SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess
of $150,000 from Investment in Dynavax Technologies Corporation to Contact
Brower Piven Before the August 19, 2013 Lead Plaintiff Deadline
STEVENSON, Md., June 19, 2013 (GLOBE NEWSWIRE) -- Brower Piven, A Professional
Corporation announces that a class action lawsuit has been commenced in the
United States District Court for the Northern District of California on behalf
of purchasers of Dynavax Technologies Corporation ("Dynavax" or the "Company")
(Nasdaq:DVAX) common stock during the period between April 26, 2012 and June
10, 2013, inclusive (the "Class Period").
If you have suffered a net loss from investment in Dynavax Technologies
Corporation common stock purchased on or after April 26, 2012, and held
through any of the revelations of negative information on November 15, 2012,
February 25, 2013, and/or June 10, 2013, as described below, you may obtain
additional information about this lawsuit and your ability to become a lead
plaintiff by contacting Brower Piven at www.browerpiven.com, by email at
email@example.com, by calling 410/415-6616, or at Brower Piven, A
Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153.
Attorneys at Brower Piven have combined experience litigating securities and
class action cases of over 60 years.
No class has yet been certified in the above action. Members of the Class will
be represented by the lead plaintiff and counsel chosen by the lead
plaintiff.If you wish to choose counsel to represent you and the Class, you
must apply to be appointed lead plaintiff no later than August 19, 2013 and be
selected by the Court.The lead plaintiff will direct the litigation and
participate in important decisions including whether to accept a settlement
and how much of a settlement to accept for the Class in the action. The lead
plaintiff will be selected from among applicants claiming the largest loss
from investment in the Company during the Class Period.
The complaint accuses the defendants of violations of the Securities Exchange
Act of 1934 by virtue of the defendants' failure to disclose during the Class
Period thatthe clinical trial for HEPLISAV, the Company's investigational
adult hepatitis B vaccine, was flawed because the trial demographics were not
representative of the population in the United States, lacked a one-year
safety follow-up typically required for vaccines, lacked information
concerning concomitant use with other vaccines, and because lacked an adequate
sized safety database, and failed to disclose the Company's failure to provide
the U.S. Food and Drug Administration ("FDA") with sufficient data concerning
its manufacturing processes and controls for HEPLISAV on its Biologics License
Application ("BLA").According to the complaint, following the Company's
November 15, 2012 disclosure that the FDA's Vaccines and Related Biological
Products Advisory Committee had voted 8 to 5 that there was not sufficient
data to adequately support the safety of HEPLISAV, the Company's February 25,
2013 disclosure that it received a Complete Response Letter from the FDA
regarding its BLA for HEPLISAV, which stated that, among other things,
HEPLISAV could not be approved for the full adult label of 18-70 years old
without additional safety data, and the Company's June 10, 2013 disclosure
that the FDA would require Dynavax to conduct additional safety trials before
the FDA would consider approving HEPLISAV (even with a restricted-use label),
the value of Dynavax shares declined significantly.
Brower Piven had previously been investigating Dynavax for potential
violations of the federal securities laws.The investigation of Dynavax was
related to positive statements issued by Dynavax concerning HEPLISAV.
If you choose to retain counsel, you may retain Brower Piven without financial
obligation or cost to you, or you may retain other counsel of your choice.You
need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
Press spacebar to pause and continue. Press esc to stop.